Novel antibodies as anticancer agents

Oncogene

Volumn 26, Issue 25, 2007, Pages 3714-3733

  Zafir Lavie, I ^a   Michaeli, Y ^a   Reiter, Y ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Anti tumor mechanisms; Antibody; Antibody fusions; Cancer immunotherapy; Targeted therapy; Tumor antigens

Indexed keywords

2C3; ANTIBODY CONJUGATE; ANTIBODY HLA A2 CONJUGATE; ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; BISPECIFIC T CELL ENGAGER MOLECULE; CARCINOEMBRYONIC ANTIGEN; CD20 ANTIBODY INTERLEUKIN 2 CONJUGATE; CETUXIMAB; CMC 544; DOXORUBICIN; DOXORUBICIN BR96 ANTIBODY CONJUGATE; EMD 273063 PLUS INTERLEUKIN 2; ERTUMAXOMAB; GEMTUZUMAB OZOGAMICIN; H R3; IBRITUMOMAB TIUXETAN; ICR 62; IMMUNOTOXIN; MATUZUMAB; MDX H210; MONOCLONAL ANTIBODY; MT 103; PACLITAXEL; PANITUMUMAB; PERTUZUMAB; RECOMBINANT DNA; RITUXIMAB; RITUXIMAB SAPORIN CONJUGATE; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBODY STRUCTURE; ANTIGEN SPECIFICITY; B CELL LYMPHOMA; BREAST CANCER; CANCER CELL; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DNA RECOMBINATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; HUMAN; HYBRIDOMA; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MALIGNANT TRANSFORMATION; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN ENGINEERING; RADIOIMMUNOTHERAPY; REVIEW; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; CYTOKINES; HUMANS; IMMUNOTHERAPY; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL;

EID: 34249693089     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210372     Document Type: Review

References (246)

1. Abastado JP, Darche S, Jouin H, Delarbre C, Gachelin G, Kourilsky P. (1989). A monoclonal antibody recognizes a subset of the H-2Dd mouse major class I antigens. Res Immunol 140:581-594.
2. Achen MG, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks AF et al. (1998). Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA 95:548-553.
3. Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS et al. (2005). Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 23:2534-2543.
4. Albanell J, Codony J, Rovira A, Mellado B, Gascon P. (2003). Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol 532:253-268.
5. Alitalo K, Tammela T, Petrova TV. (2005). Lymphangiogenesis in development and human disease. Nature 438:946-953.
6. Alvarez RD, Barnes MN, Gomez-Navarro J, Wang M, Strong TV, Arafat W et al. (2000). A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial. Clin Cancer Res 6:3081-3087.
7. Andersen PS, Stryhn A, Hansen BE, Fugger L, Engberg J, Buus S. (1996). A recombinant antibody with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. Proc Natl Acad Sci USA 93:1820-1824.
8. Antman KH, Livingston DM. (1980). Intracellular neutralization of SV40 tumor antigens following microinjection of specific antibody. Cell 19:627-635.
9. Archer GE, Sampson JH, Lorimer IA, McLendon RE, Kuan CT, Friedman AH et al. (1999). Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1. Clin Cancer Res 5:2646-2652.
10. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K et al. (1999). High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105-2116.
11. Baggiolini M. (1998). Chemokines and leukocyte traffic. Nature 392:565-568.
12. Bagshawe KD, Boden J, Boxer GM, Britton DW, Green A, Partridge T et al. (1987). A cytotoxic DNA precursor is taken up selectively by human cancer xenografts. Br J Cancer 55:299-302.
13. Bagshawe KD, Sharma SK. (1996). Cyclosporine delays host immune response to antibody enzyme conjugate in ADEPT. Transplant Proc 28:3156-3158.
14. Bagshawe KD, Springer CJ, Searle F, Antoniw P, Sharma SK, Melton RG et al. (1988). A cytotoxic agent can be generated selectively at cancer sites. Br J Cancer 58:700-703.
15. Barbieri L, Battelli MG, Stirpe F. (1993). Ribosome-inactivating proteins from plants. Biochim Biophys Acta 1154:237-282.
16. Barbieri L, Bolognesi A, Valbonesi P, Polito L, Olivieri F, Stirpe F. (2000). Polynucleotide: adenosine glycosidase activity of immunotoxins containing ribosome-inactivating proteins. J Drug Target 8:281-288.
17. Barthelemy I, Martineau D, Ong M, Matsunami R, Ling N, Benatti L et al. (1993). The expression of saporin, a ribosome-inactivating protein from the plant Saponaria officinalis, in Escherichia coli. J Biol Chem 268:6541-6548.
18. Barzilay E, Ben-Califa N, Shahar M, Kashman Y, Neumann D. (2005). Generation of a novel antigeldanamycin antibody. Biochem Biophys Res Commun 330:561-564.
19. Baselga J. (2001). The EGFR as a target for anticancer therapy - focus on cetuximab. Eur J Cancer 37(Suppl 4):S16-S22.
20. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L et al. (1996). Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744.
21. Beauchemin N, Kunath T, Robitaille J, Chow B, Turbide C, Daniels E et al. (1997). Association of biliary glycoprotein with protein tyrosine phosphatase SHP-1 in malignant colon epithelial cells. Oncogene 14:783-790.
22. Beers R, Chowdhury P, Bigner D, Pastan I. (2000). Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display. Clin Cancer Res 6:2835-2843.
23. Bergamaschi G, Perfetti V, Tonon L, Novella A, Lucotti C, Danova M et al. (1996). Saporin, a ribosome-inactivating protein used to prepare immunotoxins, induces cell death via apoptosis. Br J Haematol 93:789-794.
24. Biocca S, Neuberger MS, Cattaneo A. (1990). Expression and targeting of intracellular antibodies in mammalian cells. EMBO J 9:101-108.
25. Birchler M, Viti F, Zardi L, Spiess B, Neri D. (1999). Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment. Nat Biotechnol 17:984-988.
26. Birkle S, Zeng G, Gao L, Yu RK, Aubry J. (2003). Role of tumor-associated gangliosides in cancer progression. Biochimie 85:455-463.
27. Bodmer WF, Browning MJ, Krausa P, Rowan A, Bicknell DC, Bodmer JG. (1993). Tumor escape from immune response by variation in HLA expression and other mechanisms. Ann NY Acad Sci 690:42-49.
28. Bolognesi A, Polito L, Lubelli C, Barbieri L, Parente A, Stirpe F. (2002). Ribosome-inactivating and adenine polynucleotide glycosylase activities in Mirabilis jalapa L. tissues. J Biol Chem 277:13709-13716.
29. Brandl M, Grosse-Hovest L, Holler E, Kolb HJ, Jung G. (1999). Bispecific antibody fragments with CD20 x CD28 specificity allow effective autologous and allogeneic T-cell activation against malignant cells in peripheral blood and bone marrow cultures from patients with B-cell lineage leukemia and lymphoma. Exp Hematol 27:1264-1270.
30. Brichard V, Van Pel A, Wolfel T, Wolfel C, De Plaen E, Lethe B et al. (1993). The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 178:489-495.
31. Cahill DP, Kinzler KW, Vogelstein B, Lengauer C. (1999). Genetic instability and darwinian selection in tumours. Trends Cell Biol 9:M57-M60.
32. Cao Y. (2004). Antiangiogenic cancer therapy. Semin Cancer Biol 14:139-145.
33. Cardarelli PM, Quinn M, Buckman D, Fang Y, Colcher D, King DJ et al. (2002). Binding to CD20 by anti-B1 antibody or F(ab′)(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother 51:15-24.
34. Carmeliet P. (2003). Angiogenesis in health and disease. Nat Med 9:653-660.
35. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P et al. (2002). Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754-758.
36. Challita-Eid PM, Abboud CN, Morrison SL, Penichet ML, Rosell KE, Poles T et al. (1998). A RANTES-antibody fusion protein retains antigen specificity and chemokine function. J Immunol 161:3729-3736.
37. Chang K, Pastan I. (1996). Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 93:136-140.
38. Chari RV, Jackel KA, Bourret LA, Derr SM, Tadayoni BM, Mattocks KM et al. (1995). Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formation. Cancer Res 55:4079-4084.
39. Chen X, Shen D, Sun T, Bai J, Huang L. (1998a). Production, identification and redirected cytotoxicity of CD3/CD19 bispecific monoclonal antibody]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 20:351-356.
40. Chen YT, Gure AO, Tsang S, Stockert E, Jager E, Knuth A et al. (1998b). Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci USA 95:6919-6923.
41. Cheng TL, Wei SL, Chen BM, Chern JW, Wu MF, Liu PW et al. (1999). Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug. Br J Cancer 79:1378-1385.
42. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L et al. (1999). Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-over-expressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648.
43. Cohen CJ, Denkberg G, Lev A, Epel M, Reiter Y. (2003a). Recombinant antibodies with MHC-restricted, peptide-specific, T-cell receptor-like specificity: new tools to study antigen presentation and TCR-peptide-MHC interactions. J Mol Recognit 16:324-332.
44. Cohen CJ, Denkberg G, Segal D, Reiter Y. (2003b). Generation of recombinant immunotoxins for specific targeting of tumor-related peptides presented by MHC molecules. Methods Mol Biol 207:269-282.
45. Cohen CJ, Hoffmann N, Farago M, Hoogenboom HR, Eisenbach L, Reiter Y. (2002). Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. Cancer Res 62:5835-5844.
46. Cohen CJ, Sarig O, Yamano Y, Tomaru U, Jacobson S, Reiter Y. (2003c). Direct phenotypic analysis of human MHC class I antigen presentation: visualization, quantitation, and in situ detection of human viral epitopes using peptide-specific, MHC-restricted human recombinant antibodies. J Immunol 170:4349-4361.
47. Colombo MP, Trinchieri G. (2002). Interleukin-12 in antitumor immunity and immunotherapy. Cytokine Growth Factor Rev 13:155-168.
48. Connor JP, Felder M, Hank J, Harter J, Gan J, Gillies SD et al. (2004). Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer. J Immunother 27:211-219.
49. Csoka M, Strauss G, Debatin KM, Moldenhauer G. (1996). Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3xCD19 bispecific antibody. Leukemia 10:1765-1772.
50. de Graaf M, Boven E, Oosterhoff D, van der Meulen-Muileman IH, Huls GA, Gerritsen WR et al. (2002). A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug. Br J Cancer 86:811-818.
51. Denkberg G, Cohen CJ, Lev A, Chames P, Hoogenboom HR, Reiter Y. (2002a). Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC-restricted T cell receptor-like specificity. Proc Natl Acad Sci USA 99:9421-9426.
52. Denkberg G, Klechevsky E, Reiter Y. (2002b). Modification of a tumor-derived peptide at an HLA-A2 anchor residue can alter the conformation of the MHC-peptide complex: probing with TCR-like recombinant antibodies. J Immunol 169:4399-4407.
53. Denkberg G, Lev A, Eisenbach L, Benhar I, Reiter Y. (2003). Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen. J Immunol 171:2197-2207.
54. Denkberg G, Reiter Y. (2006). Recombinant antibodies with T-cell receptor-like specificity: novel tools to study MHC class I presentation. Autoimmun Rev 5:252-257.
55. Deshane J, Cabrera G, Grim JE, Siegal GP, Pike J, Alvarez RD et al. (1995a). Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody. Gynecol Oncol 59:8-14.
56. Deshane J, Siegal GP, Alvarez RD, Wang MH, Feng M, Cabrera G et al. (1995b). Targeted tumor killing via an intracellular antibody against erbB-2. J Clin Invest 96:2980-2989.
57. DiJoseph JF, Dougher MM, Kalyandrug LB, Armellino DC, Boghaert ER, Hamann PR et al. (2006). Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma. Clin Cancer Res 12:242-249.
58. Dreier T, Baeuerle PA, Fichtner I, Grun M, Schlereth B, Lorenczewski G et al. (2003a). T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct. J Immunol 170:4397-4402.
59. Dreier T, Baeuerle PA, Fichtner I, Grun M, Schlereth B, Lorenczewski G et al. (2003b). T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct. J Immunol 170:4397-4402.
60. Dreier T, Baeuerle PA, Fichtner I, Grun M, Schlereth B, Lorenczewski G et al. (2003c). T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct. J Immunol 170:4397-4402.
61. Dreier T, Lorenczewski G, Brandl C, Hoffmann P, Syring U, Hanakam F et al. (2002a). Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer 100:690-697.
62. Dreier T, Lorenczewski G, Brandl C, Hoffmann P, Syring U, Hanakam F et al. (2002b). Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer 100:690-697.
63. Duc HT, Rucay P, Righenzi S, Halle-Pannenko O, Kourilsky P. (1993). Monoclonal antibodies directed against T cell epitopes presented by class I MHC antigens. Int Immunol 5:4 27-431.
64. Dudley ME, Rosenberg SA. (2003). Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 3:666-675.
65. Eichhorn ME, Strieth S, Dellian M. (2004). Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives. Drug Resist Update 7:125-138.
66. Endo Y. (1988). Mechanism of action of ricin and related toxins on the inactivation of eukaryotic ribosomes. Cancer Treat Res 37:75-89.
67. Endo Y, Mitsui K, Motizuki M, Tsurugi K. (1987). The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. The site and the characteristics of the modification in 28 S ribosomal RNA caused by the toxins. J Biol Chem 262:5908-5912.
68. Engberg J, Krogsgaard M, Fugger L. (1999). Recombinant antibodies with the antigen-specific, MHC restricted specificity of T cells: novel reagents for basic and clinical investigations and immunotherapy. Immunotechnology 4:273-278.
69. Engelhard VH, Bullock TN, Colella TA, Sheasley SL, Mullins DW. (2002). Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy. Immunol Rev 188:136-146.
70. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L et al. (2002). Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20:1800-1808.
71. Falini B, Bolognesi A, Flenghi L, Tazzari PL, BroeMK, Stein H et al. (1992). Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. Lancet 339:1195-1196.
72. Favaloro EJ, Bradstock KF, Kabral A, Grimsley P, Berndt MC. (1987). Characterization of monoclonal antibodies to the human myeloid-differentiation antigen, 'gp67' (CD-33). Dis Markers 5:215-225.
73. Ferguson KM. (2004). Active and inactive conformations of the epidermal growth factor receptor. Biochem Soc Trans 32:742-745.
74. Ferrara N, Hillan KJ, Gerber HP, Novotny W. (2004). Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391-400.
75. FitzGerald K, Holliger P, Winter G. (1997). Improved tumour targeting by disulphide stabilized diabodies expressed in Pichia pastoris. Protein Eng 10:1221-1225.
76. Fleischhauer K, Tanzarella S, Wallny HJ, Bordignon C, Traversari C. (1996). Multiple HLA-A alleles can present an immunodominant peptide of the human melanoma antigen Melan-A/MART-1 to a peptide-specific HLA-A*0201 + cytotoxic T cell line. J Immunol 157:787-797.
77. Foon KA, Yang XD, Weiner LM, Belldegrun AS, Figlin RA, Crawford J et al. (2004). Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 58:984-990.
78. Francis RJ, Sharma SK, Springer C, Green AJ, Hope-Stone LD, Sena L et al. (2002). A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. Br J Cancer 87:600-607.
79. Fraser HM, Wilson H, Rudge JS, Wiegand SJ. (2005). Single injections of vascular endothelial growth factor trap block ovulation in the macaque and produce a prolonged, dose-related suppression of ovarian function. J Clin Endocrinol Metab 90:1114-1122.
80. Froscher BG, Klinman NR. (1986). Immunization with SV40-transformed cells yields mainly MHC-restricted monoclonal antibodies. J Exp Med 164:196-210.
81. Gargano N, Cattaneo A. (1997). Rescue of a neutralizing antiviral antibody fragment from an intracellular polyclonal repertoire expressed in mammalian cells. FEBS Lett 414:537-540.
82. Gately MK. (1993). Interleukin-12: a recently discovered cytokine with potential for enhancing cell-mediated immune responses to tumors. Cancer Invest 11:500-506.
83. Gibson TB, Ranganathan A, Grothey A. (2006). Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer 6:29-31.
84. Gillies SD, Lan Y, Williams S, Carr F, Forman S, Raubitschek A et al. (2005). An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma. Blood 105:3972-3978.
85. Glennie MJ, McBride HM, Worth AT, Stevenson GT. (1987). Preparation and performance of bispecific F(ab′ gamma)2 antibody containing thioether-linked Fab' gamma fragments. J Immunol 139:2367-2375.
86. Goldmacher VS, Lambert JM, Blattler WA. (1992). The specific cytotoxicity of immunoconjugates containing blocked ricin is dependent on the residual binding capacity of blocked ricin: evidence that the membrane binding and A-chain translocation activities of ricin cannot be separated. Biochem Biophys Res Commun 183:758-766.
87. Graeven U, Kremer B, Sudhoff T, Killing B, Rojo F, Weber D et al. (2006). Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. Br J Cancer 94:1293-1299.
88. Grana C, Chinol M, Robertson C, Mazzetta C, Bartolomei M, De CC et al. (2002). Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study. Br J Cancer 86:207-212.
89. Griffin JD, Linch D, Sabbath K, Larcom P, Schlossman SF. (1984). A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res 8:521-534.
90. Gutheil JC, Campbell TN, Pierce PR, Watkins JD, Huse WD, Bodkin DJ et al. (2000). Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 6:3056-3061.
91. Haagen IA, Geerars AJ, Bast EJ, de Gast GC, van de Winkel JG, de Lau WB. (1994). Evaluation of Fc gamma receptor mediated T-cell activation by two purified CD3 x CD19 bispecific monoclonal antibodies with hybrid Fc domains. Ther Immunol 1:279-287.
92. Hakomori S. (1998). Cancer-associated glycosphingolipid antigens: their structure, organization, and function. Acta Anat (Basel) 161:79-90.
93. Harari PM. (2004). Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 11:689-708.
94. Harding J, Burtness B. (2005). Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today (Barc) 41:107-127.
95. Hassan R, Bera T, Pastan I. (2004). Mesothelin: a new target for immunotherapy. Clin Cancer Res 10:3937-3942.
96. Hassan R, Lerner MR, Benbrook D, Lightfoot SA, Brackett DJ, Wang QC et al. (2002). Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. Clin Cancer Res 8:3520-3526.
97. Held G, Matsuo M, Epel M, Gnjatic S, Ritter G, Lee SY et al. (2004). Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments. Eur J Immunol 34:2919-2929.
98. Hoffmann P, Hofmeister R, Brischwein K, Brandl C, Crommer S, Bargou R et al. (2005b). Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer 115:98-104.
99. Hoffmann P, Hofmeister R, Brischwein K, Brandl C, Crommer S, Bargou R et al. (2005a). Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer 115:98-104.
100. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M et al. (2002). VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99:11393-11398.
101. Holliger P, Manzke O, Span M, Hawkins R, Fleischmann B, Qinghua L et al. (1999). Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins. Cancer Res 59:2909-2916.
102. Holliger P, Prospero T, Winter G. (1993). 'Diabodies': small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 90:6444-6448.
103. Hoogenboom HR, de Bruine AP, Hufton SE, Hoet RM, Arends JW, Roovers RC. (1998). Antibody phage display technology and its applications. Immunotechnology 4:1-20.
104. Howard OM, Dong HF, Shirakawa AK, Oppenheim JJ. (2000). LEC induces chemotaxis and adhesion by interacting with CCR1 and CCR8. Blood 96:840-845.
105. Huang SM, Bock JM, Harari PM. (1999). Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59:1935-1940.
106. Hyland S, Beerli RR, Barbas CF, Hynes NE, Wels W. (2003). Generation and functional characterization of intracellular antibodies interacting with the kinase domain of human EGF receptor. Oncogene 22:1557-1567.
107. Irie RF, Ollila DW, O'Day S, Morton DL. (2004). Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma. Cancer Immunol Immunother 53:110-117.
108. Jager E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jager D et al. (1998). Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 187:265-270.
109. Jhanwar YS, Divgi C. (2005). Current status of therapy of solid tumors. J Nucl Med 46(Suppl 1):141S-150S.
110. Juweid ME, Hajjar G, Swayne LC, Sharkey RM, Suleiman S, Herskovic T et al. (1999). Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma. Cancer 85:1828-1842.
111. Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L et al. (2001). Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 19:3918-3928.
112. Karashima T, Sweeney P, Slaton JW, Kim SJ, Kedar D, Izawa JI et al. (2002). Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clin Cancer Res 8:1253-1264.
113. Katayose Y, Kudo T, Suzuki M, Shinoda M, Saijyo S, Sakurai N et al. (1996). MUC1-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth. Cancer Res 56:4205-4212.
114. Kawakami Y, Dang N, Wang X, Tupesis J, Robbins PF, Wang RF et al. (2000). Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. J Immunother 23:17-27.
115. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR et al. (1994). Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 180:347-352.
116. Kerr DE, Schreiber GJ, Vrudhula VM, Svensson HP, Hellstrom I, Hellstrom KE et al. (1995). Regressions and cures of melanoma xenografts following treatment with monoclonal antibody beta-lactamase conjugates in combination with anticancer prodrugs. Cancer Res 55:3558-3563.
117. Khong HT, Restifo NP. (2002). Natural selection of tumor variants in the generation of 'tumor escape' phenotypes. Nat Immunol 3:999-1005.
118. Kiessling R, Wasserman K, Horiguchi S, Kono K, Sjoberg J, Pisa P et al. (1999). Tumor-induced immune dysfunction. Cancer Immunol Immunother 48:353-362.
119. Kiewe P, Hasmuller S, Kahlert S, Heinrigs M, Rack B, Marme A et al. (2006). Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res 12:3085-3091.
120. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS et al. (1993). Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841-844.
121. King DM, Albertini MR, Schalch H, Hank JA, Gan J, Surfus J et al. (2004). Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J Clin Oncol 22:4463-4473.
122. Kinugasa T, Kuroki M, Takeo H, Matsuo Y, Ohshima K, Yamashita Y et al. (1998). Expression of four CEA family antigens (CEA, NCA, BGP and CGM2) in normal and cancerous gastric epithelial cells: up-regulation of BGP and CGM2 in carcinomas. Int J Cancer 76:148-153.
123. Kipriyanov SM. (2002). Generation of bispecific and tandem diabodies. Methods Mol Biol 178:317-331.
124. Kipriyanov SM, Moldenhauer G, Strauss G, Little M. (1998). Bispecific CD3 x CD19 diabody for T cell-mediated lysis of malignant human B cells. Int J Cancer 77:763-772.
125. Kohler G, Milstein C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-497.
126. Kollmannsberger C, Schittenhelm M, Honecker F, Tillner J, Weber D, Oechsle K et al. (2006). A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). Ann Oncol 17:1007-1013.
127. Korn T, Nettelbeck DM, Volkel T, Muller R, Kontermann RE. (2004). Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells: a comparative analysis of bacterially expressed single-chain diabody and tandem scFv. J Gene Med 6:642-651.
128. Kranz DM, Gruber M, Wilson ER. (1995). Properties of bispecific single chain antibodies expressed in Escherichia coli. J Hematother 4:403-408.
129. Kreitman RJ, Squires DR, Stetler-Stevenson M, Noel P, FitzGerald DJ, Wilson WH et al. (2005). Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 23:6719-6729.
130. Kushner BH, Kramer K, Cheung NK. (2001). Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol 19:4189-4194.
131. Lengauer C, Kinzler KW, Vogelstein B. (1998). Genetic instabilities in human cancers. Nature 396:643-649.
132. Leonard JP, Coleman M, Ketas JC, Chadburn A, Furman R, Schuster MW et al. (2004). Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin Cancer Res 10:5327-5334.
133. Lewis LD, Beelen AP, Cole BF, Wallace PK, Fisher JL, Waugh MG et al. (2002). The pharmacokinetics of the bispecific antibody MDX-H210 when combined with interferon gamma-1b in a multiple-dose phase I study in patients with advanced cancer. Cancer Chemother Pharmacol 49:375-384.
134. Li J, Hu P, Khawli LA, Epstein AL. (2003). LEC/chTNT-3 fusion protein for the immunotherapy of experimental solid tumors. J Immunother 26:320-331.
135. Li J, Hu P, Khawli LA, Yun A, Epstein AL. (2004). chTNT-3/ hu IL-12 fusion protein for the immunotherapy of experimental solid tumors. Hybrid Hybridomics 23:1-10.
136. Loffler A, Gruen M, Wuchter C, Schriever F, Kufer P, Dreier T et al. (2003). Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Leukemia 17:900-909.
137. Loffler A, Kufer P, Lutterbuse R, Zettl F, Daniel PT, Schwenkenbecher JM et al. (2000a). A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95:2098-2103.
138. Loffler A, Kufer P, Lutterbuse R, Zettl F, Daniel PT, Schwenkenbecher JM et al. (2000b). A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95:2098-2103.
139. Maletz K, Kufer P, Mack M, Raum T, Pantel K, Riethmuller G et al. (2001a). Bispecific single-chain antibodies as effective tools for eliminating epithelial cancer cells from human stem cell preparations by redirected cell cytotoxicity. Int J Cancer 93:409-416.
140. Maletz K, Kufer P, Mack M, Raum T, Pantel K, Riethmuller G et al. (2001b). Bispecific single-chain antibodies as effective tools for eliminating epithelial cancer cells from human stem cell preparations by redirected cell cytotoxicity. Int J Cancer 93:409-416.
141. Manzke O, Tesch H, Borchmann P, Wolf J, Lackner K, Gossmann A et al. (2001a). Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. I. Clinical phase I evaluation. Int J Cancer 91:508-515.
142. Manzke O, Tesch H, Lorenzen J, Diehl V, Bohlen H. (2001b). Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. II. Assessment of cellular immune responses. Int J Cancer 91:516-522.
143. Mapara MY, Sykes M. (2004). Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 22:1136-1151.
144. Marasco WA. (1997b). Intrabodies: turning the humoral immune system outside in for intracellular immunization. Gene Ther 4:11-15.
145. Marasco WA. (1997a). Intrabodies: turning the humoral immune system outside in for intracellular immunization. Gene Therapy 4:11-15.
146. Matthey B, Borchmann P, Schnell R, Tawadros S, Lange H, Huhn M et al. (2004). Metalloproteinase inhibition augments antitumor efficacy of the anti-CD30 immunotoxin Ki-3(scFv)-ETA' against human lymphomas in vivo. Int J Cancer 111:568-574.
147. McKeage K, Perry CM. (2002). Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 62:209-243.
148. McNeel DG, Eickhoff J, Lee FT, King DM, Alberti D, Thomas JP et al. (2005). Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clin Cancer Res 11:7851-7860.
149. Mehta K, Ocanas L, Malavasi F, Marks JW, Rosenblum MG. (2004). Retinoic acid-induced CD38 antigen as a target for immunotoxin-mediated killing of leukemia cells. Mol Cancer Ther 3:345-352.
150. Miescher S, Whiteside TL, Carrel S, von FV. (1986). Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J Immunol 136:1899-1907.
151. Mocellin S, Wang E, Marincola FM. (2001). Cytokines and immune response in the tumor microenvironment. J Immunother 24:392-407.
152. Modjtahedi H, Moscatello DK, Box G, Green M, Shotton C, Lamb DJ et al. (2003). Targeting of cells expressing wildtype EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy. Int J Cancer 105:273-280.
153. Mule JJ, Rea YJL. (1987). Identification of cellular mechanisms operation in vivo during the regression of established pulmonary metastases by the systemic administration of high dose recombinant interleukin-2. J Immunol 139:285-295.
154. Multani PS, O'Day S, Nadler LM, Grossbard ML. (1998). Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma. Clin Cancer Res 4:2599-2604.
155. Nagane M, Lin H, Cavenee WK, Huang HJ. (2001). Aberrant receptor signaling in human malignant gliomas: mechanisms and therapeutic implications. Cancer Lett 162(Suppl):S17-S21.
156. Napier MP, Sharma SK, Springer CJ, Bagshawe KD, Green AJ, Martin J et al. (2000). Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma. Clin Cancer Res 6:76 5-772.
157. Offner S, Hofmeister R, Romaniuk A, Kufer P, Baeuerle PA. (2006). Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol 43:763-771.
158. Ogg GS, Dunbar PR, Cerundolo V, McMichael AJ, Lemoine NR, Savage P. (2000). Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes. Br J Cancer 82:1058-1062.
159. Okamoto I, Kenyon LC, Emlet DR, Mori T, Sasaki J, Hirosako S et al. (2003). Expression of constitutively activated EGFRvIII in non-small cell lung cancer. Cancer Sci 94:50-56.
160. Omidfar K, Rasaee MJ, Modjtahedi H, Forouzandeh M, Taghikhani M, Bakhtiari A et al. (2004). Production and characterization of a new antibody specific for the mutant EGF receptor, EGFRvIII, in Camelus bactrianus. Tumour Biol 25:179-187.
161. Osta WA, Chen Y, Mikhitarian K, Mitas M, Salem M, Hannun YA et al. (2004). EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 64:5818-5824.
162. Oved K, Lev A, Noy R, Segal D, Reiter Y. (2005). Antibody-mediated targeting of human single-chain class I MHC with covalently linked peptides induces efficient killing of tumor cells by tumor or viral-specific cytotoxic T lymphocytes. Cancer Immunol Immunother 54:867-879.
163. Paganelli G, Bartolomei M, Ferrari M, Cremonesi M, Broggi G, Maira G et al. (2001). Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results. Cancer Biother Radiopharm 16:227-235.
164. Paganelli G, Malcovati M, Fazio F. (1991). Monoclonal antibody pretargetting techniques for tumour localization: the avidin-biotin system. International Workshop on Techniques for Amplification of Tumour Targetting. Nucl Med Commun 12:211-234.
165. Pascolo S, Schirle M, Guckel B, Dumrese T, Stumm S, Kayser S et al. (2001). A MAGE-A1 HLA-A A*0201 epitope identified by mass spectrometry. Cancer Res 61:4072-4077.
166. Pastan I, Chaudhary V, FitzGerald DJ. (1992). Recombinant toxins as novel therapeutic agents. Annu Rev Biochem 61:331-354.
167. Peumans WJ, Hao Q, Van Damme EJ. (2001). Ribosome-inactivating proteins from plants: more than RNA N-glycosidases? FASEB J 15:1493-1506.
168. Pittet MJ, Valmori D, Dunbar PR, Speiser DE, Lienard D, Lejeune F et al. (1999). High frequencies of naive Melan-A/ MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 190:705-715.
169. Plaksin D, Polakova K, McPhie P, Margulies DH. (1997). A three-domain T cell receptor is biologically active and specifically stains cell surface MHC/peptide complexes. J Immunol 158:2218-2227.
170. Polito L, Bolognesi A, Tazzari PL, Farini V, Lubelli C, Zinzani PL et al. (2004). The conjugate Rituximab/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with Fludarabine. Leukemia 18:1215-1222.
171. Porgador A, Yewdell JW, Deng Y, Bennink JR, Germain RN. (1997). Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 6:715-726.
172. Rae JM, Scheys JO, Clark KM, Chadwick RB, Kiefer MC, Lippman ME. (2004). EGFR and EGFRvIII expression in primary breast cancer and cell lines. Breast Cancer Res Treat 87:87-95.
173. Reist CJ, Archer GE, Kurpad SN, Wikstrand CJ, Vaidyanathan G, Willingham MC et al. (1995). Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts. Cancer Res 55:4375-4382.
174. Reiter Y, Di CA, Fugger L, Engberg J, Pastan I. (1997). Peptide-specific killing of antigen-presenting cells by a recombinant antibody-toxin fusion protein targeted to major histocompatibility complex/peptide class I complexes with T cell receptor-like specificity. Proc Natl Acad Sci USA 94:4631-4636.
175. Repp R, van Ojik HH, Valerius T, Groenewegen G, Wieland G, Oetzel C et al. (2003). Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaR-I x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer. Br J Cancer 89:2234-2243.
176. Reusch U, Sundaram M, Davol PA, Olson SD, Davis JB, Demel K et al. (2006). Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model. Clin Cancer Res 12:183-190.
177. Riesenberg R, Buchner A, Pohla H, Lindhofer H. (2001). Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3). J Histochem Cytochem 49:911-917.
178. Robert B, Guillaume P, Luescher I, Romero P, Mach JP. (2000). Antibody-conjugated MHC class I tetramers can target tumor cells for specific lysis by T lymphocytes. Eur J Immunol 30:3165-3170.
179. Robinson BW, Mukherjee SA, Davidson A, Morey S, Musk AW, Ramshaw I et al. (1998). Cytokine gene therapy or infusion as treatment for solid human cancer. J Immunother 21:211-217.
180. Romero P, Valmori D, Pittet MJ, Zippelius A, Rimoldi D, Levy F et al. (2002). Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol Rev 188:81-96.
181. Rosenberg SA, Yang JC, White DE, Steinberg SM. (1998). Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 228:307-319.
182. Rossi D, Zlotnik A. (2000). The biology of chemokines and their receptors. Annu Rev Immunol 18:217-242.
183. Rowinsky EK, Schwartz GH, Gollob JA, Thompson JA, Vogelzang NJ, Figlin R et al. (2004). Safety, pharmacokinetics, and activity of ABX-EGF, a fully human antiepidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 22:3003-3015.
184. Sacchi S, Federico M, Dastoli G, Fiorani C, Vinci G, Clo V et al. (2001). Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab. Crit Rev Oncol Hematol 37:13-25.
185. Saleh MN, Sugarman S, Murray J, Ostroff JB, Healey D, Jones D et al. (2000). Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. J Clin Oncol 18:2282-2292.
186. Sanderson RJ, Hering MA, James SF, Sun MM, Doronina SO, Siadak AW et al. (2005). In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res 11:843-852.
187. Schaed SG, Klimek VM, Panageas KS, Musselli CM, Butterworth L, Hwu WJ et al. (2002). T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201 + melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants. Clin Cancer Res 8:967-972.
188. Schlereth B, Fichtner I, Lorenczewski G, Kleindienst P, Brischwein K, da Silva A et al. (2005). Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct. Cancer Res 65:2882-2889.
189. Schlereth B, Quadt C, Dreier T, Kufer P, Lorenczewski G, Prang N et al. (2006). T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Cancer Immunol Immunother 55:503-514.
190. Schnell R, Staak O, Borchmann P, Schwartz C, Matthey B, Hansen H et al. (2002). A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4. dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. Clin Cancer Res 8:1779-1786.
191. Schwaab T, Lewis LD, Cole BF, Deo Y, Fanger MW, Wallace P et al. (2001). Phase I pilot trial of the bispecific antibody MDXH210 (anti-Fc gamma RI x anti-HER-2/ neu) in patients whose prostate cancer overexpresses HER-2/neu. J Immunother 24:79-87.
192. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A et al. (2001). Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19:2587-2595.
193. Shan D, Ledbetter JA, Press OW. (2000). Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 48:673-683.
194. Sharkey RM, Goldenberg DM. (2005a). Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med 46(Suppl 1):115S-127S.
195. Sharkey RM, Hajjar G, Yeldell D, Brenner A, Burton J, Rubin A et al. (2005b). A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer. J Nucl Med 46:620-633.
196. Shaw DR, Harrison G, Sun LK, Shearman C, Ghrayeb J, McKinney S et al. (1988). Human lymphocyte and monocyte lysis of tumor cells mediated by a mouse/human IgG1 chimeric monoclonal antibody. J Biol Response Mod 7:204-211.
197. Smith J, Kontermann RE, Embleton J, Kumar S. (2005). Antibody phage display technologies with special reference to angiogenesis. FASEB J 19:331-341.
198. Smith-Jones PM, Solit DB. (2004). Generation of DOTA-conjugated antibody fragments for radioimmunoimaging. Methods Enzymol 386:262-275.
199. Soiffer RJ, Robertson MJ, Murray C, Cochran K, Ritz J. (1993). Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies. Blood 82:2790-2796.
200. SperrWR, Florian S, Hauswirth AW, Valent P. (2005). CD 33 as a target of therapy in acute myeloid leukemia: current status and future perspectives. Leuk Lymphoma 46:1115-1120.
201. Stevenson GT, Pindar A, Slade CJ. (1989). A chimeric antibody with dual Fc regions (bisFabFc) prepared by manipulations at the IgG hinge. Anticancer Drug Des 3: 219-230.
202. Stocks M. (2005). Intrabodies as drug discovery tools and therapeutics. Curr Opin Chem Biol 9:359-365.
203. Strube RW, Chen SY. (2002). Characterization of anti-cyclin E single-chain Fv antibodies and intrabodies in breast cancer cells: enhanced intracellular stability of novel sFv-F(c) intrabodies. J Immunol Methods 263:149-167.
204. Takai N, Jain A, Kawamata N, Popoviciu LM, Said JW, Whittaker S et al. (2005). 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. Cancer 104:2701-2708.
205. Tamminen WL, Wraith D, Barber BH. (1987). Searching for MHC-restricted anti-viral antibodies: antibodies recognizing the nucleoprotein of influenza virus dominate the serological response of C57BL/6 mice to syngeneic influenza-infected cells. Eur J Immunol 17:999-1006.
206. Tiebout RF, Boxtel-Oosterhof F, Stricker EA, Zeijlemaker WP. (1987). A human hybrid hybridoma. J Immunol 139:3402-3405.
207. Tijink BM, Neri D, Leemans CR, Budde M, Dinkelborg LM, Stigter-van WM et al. (2006). Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med 47:1127-1135.
208. Tolcher AW, Sugarman S, Gelmon KA, Cohen R, Saleh M, Isaacs C et al. (1999). Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol 17:478-484.
209. Torres LA, Perera A, Batista JF, Hernandez A, Crombet T, Ramos M et al. (2005). Phase I/II clinical trial of the humanized anti-EGF-r monoclonal antibody h-R3 labelled with 99mTc in patients with tumour of epithelial origin. Nucl Med Commun 26:1049-1057.
210. Tse E, Lobato MN, Forster A, Tanaka T, Chung GT, Rabbitts TH. (2002). Intracellular antibody capture technology: application to selection of intracellular antibodies recognising the BCR-ABL oncogenic protein. J Mol Biol 317:85-94.
211. Tur MK, Huhn M, Thepen T, Stocker M, Krohn R, Vogel S et al. (2003). Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells. Cancer Res 63:8414-8419.
212. Verheul HM, Voest EE, Schlingemann RO. (2004). Are tumours angiogenesis-dependent? J Pathol 202:5-13.
213. Visintin M, Settanni G, Maritan A, Graziosi S, Marks JD, Cattaneo A. (2002). The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodies. J Mol Biol 317:73-83.
214. Visseren MJ, van der Burg SH, van dV, Brandt RM, Schrier PI, van der BP et al. (1997). Identification of HLA-A*0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product. Int J Cancer 73:125-130.
215. Viti F, Tarli L, Giovannoni L, Zardi L, Neri D. (1999). Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res 59:347-352.
216. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L et al. (2002). Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726.
217. Waldmann TA. (2002). The IL-2/IL-15 receptor systems: targets for immunotherapy. J Clin Immunol 22:51-56.
218. Waldmann TA, Pastan IH, Gansow OA, Junghans RP. (1992). The multichain interleukin-2 receptor: a target for immunotherapy. Ann Intern Med 116:148-160.
219. Wallace PM, MacMaster JF, Smith VF, Kerr DE, Senter PD, Cosand WL. (1994). Intratumoral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocytosine. Cancer Res 54:2719-2723.
220. Weng WK, Levy R. (2003). Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21:3940-3947.
221. Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U et al. (2006). Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 94:128-135.
222. Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G et al. (2004). Frequent EpCam protein expression in human carcinomas. Hum Pathol 35:122-128.
223. Whiteside TL. (1999). Signaling defects in T lymphocytes of patients with malignancy. Cancer Immunol Immunother 48:346-352.
224. Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN et al. (1995). Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 55:3140-3148.
225. Wimberger P, Xiang W, Mayr D, Diebold J, Dreier T, Baeuerle PA et al. (2003). Efficient tumor cell lysis by autologous, tumor-resident T lymphocytes in primary ovarian cancer samples by an EP-CAM-/CD3-bispecific antibody. Int J Cancer 105:241-248.
226. Witlox MA, Van B, V, Grill J, Haisma HJ, Schaap G, Bras J et al. (2002). Epidermal growth factor receptor targeting enhances adenoviral vector based suicide gene therapy of osteosarcoma. J Gene Med 4:510-516.
227. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R et al. (2002). Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20:2453-2463.
228. Wolf E, Hofmeister R, Kufer P, Schlereth B, Baeuerle PA. (2005). BiTEs: bispecific antibody constructs with unique anti-tumor activity. Drug Discov Today 10:1237-1244.
229. Wolfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Meyer zum Buschenfelde KH et al. (1994). Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 24:759-764.
230. Wulff C, Wilson H, Wiegand SJ, Rudge JS, Fraser HM. (2002). Prevention of thecal angiogenesis, antral follicular growth, and ovulation in the primate by treatment with vascular endothelial growth factor Trap R1R2. Endocrinology 143:2797-2807.
231. Wulfing C, Pluckthun A. (1994). Correctly folded T-cell receptor fragments in the periplasm of Escherichia coli. Influence of folding catalysts. J Mol Biol 242:655-669.
232. Wylie DE, Sherman LA, Klinman NR. (1982). Participation of the major histocompatibility complex in antibody recognition of viral antigens expressed on infected cells. J Exp Med 155:403-414.
233. Xiong D, Xu Y, Liu H, Peng H, Shao X, Lai Z et al. (2002). Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 x anti-CD3 bispecific diabody. Cancer Lett 177:29-39.
234. Yagita H, Takeda K, Hayakawa Y, Smyth MJ, Okumura K. (2004). TRAIL and its receptors as targets for cancer therapy. Cancer Sci 95:777-783.
235. Yamano Y, Cohen CJ, Takenouchi N, Yao K, Tomaru U, Li HC et al. (2004). Increased expression of human T lymphocyte virus type I (HTLV-I) Tax11-19 peptide-human histocompatibility leukocyte antigen A*201 complexes on CD4+ CD25+ T Cells detected by peptide-specific, major histocompatibility complex-restricted antibodies in patients with HTLV-I-associated neurologic disease. J Exp Med 199:1367-1377.
236. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG. (2001). Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 38:17-23.
237. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG, Jakobovits A. (1999). Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 59:1236-1243.
238. Yarden Y. (2001). The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 37(Suppl 4):S3-S8.
239. Yu JL, Rak JW, Coomber BL, Hicklin DJ, Kerbel RS. (2002). Effect of p53 status on tumor response to antiangiogenic therapy. Science 295:1526-1528.
240. Yu R, Li SC, Wu BC, Liu H, Ye LL, Chen ZL. (2005). Expression, identification and bioactivity characterization of an anti-CD3/anti-CD20 bispecific single-chain antibody]. Sheng Wu Gong Cheng Xue Bao 21:289-293.
241. Zaki MH, Wysocka M, Everetts SE, Wang KS, French LE, Ritz J et al. (2002). Synergistic enhancement of cell-mediated immunity by interleukin-12 plus interleukin-2: basis for therapy of cutaneous T cell lymphoma. J Invest Dermatol 118:366-371.
242. Zardi L, Carnemolla B, Siri A, Petersen TE, Paolella G, Sebastio G et al. (1987). Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J 6:2337-2342.
243. Zein N, Sinha AM, McGahren WJ, Ellestad GA. (1988). Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 240:1198-1201.
244. Zhang W, Ran S, Sambade M, Huang X, Thorpe PE. (2002). A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model. Angiogenesis 5:35-44.
245. Zhou H, Stanners CP, Fuks A. (1993). Specificity of anticarcinoembryonic antigen monoclonal antibodies and their effects on CEA-mediated adhesion. Cancer Res 53:3817-3822.
246. Zhu Z, Zapata G, Shalaby R, Snedecor B, Chen H, Carter P. (1996). High level secretion of a humanized bispecific diabody from Escherichia coli. Biotechnology (NY) 14:192-196.